drugset / Trial / NCT02420938
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if urelumab given in combination with rituximab can help to control CLL or SLL. The safety of the drug combination will also be studied.
Timeline
- Start
- 2015-07
- Primary completion
- 2020-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 8 mg | Intravenous |